Evaxion to Unveil New Immune Data for Personalized Cancer Vaccine…

Event summary

Evaxion will present new immune data for its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting on November 6-7, 2026.
The data stems from a phase 2 trial of EVX-01 in combination with Merck's KEYTRUDA® in advanced melanoma patients.
Two-year data from the trial showed a 75% Objective Response Rate (ORR) and 92% durable clinical benefit.
The SITC presentation will focus on systemic immunomodulatory effects beyond vaccine-specific T-cell responses.

The big picture

Evaxion's presentation comes amid growing interest in AI-designed immunotherapies, with EVX-01's personalized approach targeting a high unmet need in advanced melanoma. The data could validate the company's AI-Immunology™ platform as a scalable solution for cancer vaccines, potentially attracting partnerships or acquisition interest. The focus on systemic immune modulation suggests broader applications beyond neoantigen-specific responses, which could expand EVX-01's therapeutic potential.

What we're watching

Clinical Efficacy: Whether the three-year data will demonstrate sustained efficacy of EVX-01 as a stand-alone therapy.
Market Differentiation: How the immune modulation data positions EVX-01 against competing cancer immunotherapies.
Regulatory Pathway: The pace at which Evaxion can advance EVX-01 toward potential approval based on these results.